Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

eFFECTOR Therapeutics

- PMLiVE

Pfizer’s Xalkori approved for wider use in Europe

Labelupdate gives the lung cancer therapy a new first-line indication

- PMLiVE

Pfizer signs high-level deal with GPCR specialist Heptares

Wide-rangingdeal will involve up to 10 drug targets

Michael Parini moves from Pfizer to Vertex

Will be the USbiotech's chief legal officer

- PMLiVE

Pfizer and Allergan merger faces opposition over tax

Companiesagree deal to boost Pfizer's standing as world's largest pharma company

- PMLiVE

Cellectis gets big pharma partners for CAR-T therapy

Pfizer, Servier and Cellectis in three-way deal to develop CAR-T immunotherapy

- PMLiVE

FDA deems Merck KGaA and Pfizer’s avelumab a breakthrough

Could become first-in-class treatment for Merkel cell carcinoma

- PMLiVE

Merck KGaA and Pfizer move avelumab into late-stage trials

Begin phase III studies of the monoclonal antibody in lung cancer

Why is the UK lagging behind the rest of Europe in cancer survival?

Say Communications, London healthcare PR agency, discusses the latest technologies that will improve cancer survival rates in UK

Say Communications

- PMLiVE

Allergan/Pfizer takeover talks confirmed

Talks still in early stage with no certainty of deal

- PMLiVE

Is Pfizer eyeing a merger with Allergan?

Combined company value could be $330bn

EU flag

CHMP October meeting gives recommendations for Pfizer and MSD

But the regulatory advisors sound note ofcaution on Biogen’s Tecfidera

- PMLiVE

GSK and J&J back new UK dementia discovery fund

Pharma giants collaborate with government to find new treatments

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links